Sugi Predict

Sugi Predict / Compounds / SCHEMBL1497379

SCHEMBL1497379

SCHEMBL1497379

Clc1cc(Cl)c2sccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.47
▸ MKNK2 Q9HBH9 1/20 0.47
▸ ADORA2A P29274 4/20 0.42
▸ ADORA1 P30542 4/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PDPK1 O15530 1/20 0.39
▸ POLB P06746 1/20 0.37
▸ RAB9A P51151 3/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ CTDSP1 Q9GZU7 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ DYRK1A Q13627 2/20 0.35
▸ TUBB4A P04350 1/20 0.35
▸ TUBB P07437 1/20 0.35
▸ TUBA3C P0DPH7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29484929 1.00 AXL (0.47) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL31297584 0.80 AXL (0.44) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL31745018 0.80 AXL (0.44) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL2541197 0.80 AXL (0.44) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL31612708 0.77 NT5E (0.46) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL19267957 0.76 AXL (0.41) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL31550249 0.76 ADORA2A (0.41) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL12128455 0.76 HTT (0.44) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL30577561 0.76 AXL (0.41) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL8189640 0.76 PDGFRB (0.43) AXLMKNK1MKNK2ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 — — EP disclosed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 — — US disclosed
EP-4694893-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME Therapeutics LLC (US) 2026-02-18 — — EP disclosed
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-08-26 — — US disclosed
EP-4536362-A1 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS Incyte Corporation (US) 2025-04-16 — — EP disclosed
WO-2025002491-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES MASARYKOVA UNIVERZITA (CZ) 2025-01-02 — — WO disclosed
EP-4483954-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2025-01-01 — — EP disclosed
WO-2024233848-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2024-11-14 — — WO disclosed
US-20240368167-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-11-07 — — US disclosed
WO-2024216229-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2024-10-17 — — WO disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 — — US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 — — US disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 — — US disclosed
WO-2011031896-A2 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-03-17 — — WO disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 — — US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 — — US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 — — US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 — — US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 — — EP disclosed
WO-2000071524-A1 2-NH-PYRIDONES AND PYRIMIDONES AS MRS INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2000-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368167-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, PARP12, ENTPD2 AXL 1871/4885MKNK1 3504/4885MKNK2 3241/4885
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 AXL 1871/4885MKNK1 3504/4885MKNK2 3241/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B AXL 1446/4885MKNK1 4340/4885MKNK2 4241/4885
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R AXL 2931/4885MKNK1 1020/4885MKNK2 970/4885
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF PIK3CA, PIK3CB, PIK3C2B AXL 549/4885MKNK1 130/4885MKNK2 131/4885
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 AXL 4760/4885MKNK1 316/4885MKNK2 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.